Proceeds from collaborators Proceeds from Collaborators Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Range [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Net change in operating items: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Effect of foreign exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Purchase of investments in marketable securities Payments to Acquire Investments Total other income Nonoperating Income (Expense) Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Deferred license revenue, current Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Shareholders’ equity Equity [Text Block] Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from issuance of shares under the agreement Proceeds from Issuance of Common Stock Effective annual interest rate on royalty liability Effective Annual Interest Rate Of Royalty Liability Effective Annual Interest Rate Of Royalty Liability Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Issuance of common shares pursuant to exercise of ESPP Proceeds from Stock Plans Ownership [Axis] Ownership [Axis] Short Term Marketable Securities Investments in marketable securities, current [Member] Investments in marketable securities, current Issuance of common shares upon vesting of RSUs Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Customer [Axis] Customer [Axis] Realized gains or losses Debt Securities, Realized Gain (Loss) Current liabilities: Liabilities, Current [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in USD per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Issuance of common shares pursuant to the Open Market Sale Agreement Stock Issued During Period, Value, New Issues, Open Market Sale Agreement Stock Issued During Period, Value, New Issues, Open Market Sale Agreement Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Premium on closing stock price ($ paid) Premium on closing stock price ($ paid) Premium on closing stock price ($ paid) Weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Investments in marketable securities, current Investments, Fair Value Disclosure Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Common Stock, Value, Subscriptions Expired Common Stock, Value, Subscriptions Expired Common Stock, Value, Subscriptions Expired One-Time Upfront Cash Payment One-Time Upfront Cash Payment [Member] One-Time Upfront Cash Payment Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Royalty interest sold, annual revenue threshold of highest tier Annual Revenue Threshold Annual Revenue Threshold Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Investments in marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity Equity, Attributable to Parent [Abstract] Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Total deferred license revenue Contract with Customer, Liability Issuance of common shares pursuant to exercise of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc [Member] Alnylam Pharmaceuticals, Inc Research and development accruals Accrued Research And Development Research and development accruals Executive Category: Executive Category [Axis] Jan 2020 Prospectus Supplement Jan 2020 Prospectus Supplement [Member] Jan 2020 Prospectus Supplement Significant accounting policies Significant Accounting Policies [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Liability related to sale of future royalties Net liability related to sale of future royalties - beginning balance Net liability related to sale of future royalties - ending balance Liability Related To Sale Of Future Royalties, Noncurrent Liability Related To Sale Of Future Royalties, Noncurrent Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Options granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Contingencies and Commitments [Table] Contingencies and Commitments [Table] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Sale Agreement Sale Agreement [Member] Sale Agreement Measurement Frequency [Axis] Measurement Frequency [Axis] Lease liability, non-current Operating Lease, Liability, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Number of royalty entitlements Royalty Entitlements Royalty Entitlements Non-cash royalty revenue Non-Cash Royalty [Member] Non-Cash Royalty Non-cash royalty revenue Liability From Sale Of Future Royalties, Non Cash Royalty Income Liability From Sale Of Future Royalties, Non Cash Royalty Income Marketable securities Marketable Securities [Table Text Block] Sub-licensing revenue percentage Sub-licensing revenue Percentage Sub-licensing revenue Percentage Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Accrued investment income receivable Accrued Investment Income Receivable Issuance of common shares pursuant to the Open Market Sale Agreement (in shares) Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement Number of shares issued under agreement (in sales) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] Revenues Revenues Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Payroll accruals Accrued Payroll Current Accrued Payroll Current Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type Award Type [Axis] Anti-dilutive common shares excluded from calculation of loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Contract Termination Contract Termination [Member] Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] US government agency bonds US Government Agency Bonds [Member] US Government Agency Bonds [Member] Future royalty payments Royalty Payable Represents the royalty payable. Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Debt Securities, Available-for-Sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number Other deferred costs, gross Other Deferred Costs, Gross Lease liability, current Operating Lease, Liability, Current Revenue from collaborations and licenses License [Member] Issuance of common shares pursuant to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Shell Company Entity Shell Company Investments in marketable securities, non-current Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Vaccitech Barinthus [Member] Barinthus Counterparty Name [Domain] Counterparty Name [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents US Government Securities, at Carrying Value US Government Securities, at Carrying Value Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common shares, shares issued (in shares) Common Stock, Shares, Issued Disposition of investments in marketable securities Proceeds from Sale, Maturity and Collection of Investments Cash severance Severance Costs Security Exchange Name Security Exchange Name Total Assets, Fair Value Disclosure Long-term debt Long-Term Debt Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Jan 2020 Registration Stmt Jan 2020 Registration Stmt [Member] Jan 2020 Registration Stmt Collaborations, contracts and licensing agreements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from Issuance of Common Stock, Open Market Sale agreement Proceeds from Issuance of Common Stock, Open Market Sale agreement Business Acquisition [Axis] Business Acquisition [Axis] Subsequent Event Subsequent Event [Member] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] ONPATTRO ONPATTRO, global net sales [Member] ONPATTRO, global net sales Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Collaborations and licenses Collaboration And Contracts [Member] Collaboration And Contracts [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling interest, ownership percentage by noncontrolling owners Subsidiary, Ownership Percentage, Noncontrolling Owner Development and regulatory milestones payment per royalty, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty License Agreement Maximum Development And Regulatory Royalty Payment per Royalty Grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Class of Stock [Line Items] Class of Stock [Line Items] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Tax Identification Number Entity Tax Identification Number Equity investment Equity Method Investments Range [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Non-cash items: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount US government bonds US Government Bonds [Member] US Government Bonds [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue from collaborations and licenses and Deferred Revenue Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] OMERS OMERS [Member] OMERS Unrealized gain on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Mar 2021 Prospectus Supplement Agreement Mar 2021 Prospectus Supplement Agreement [Member] Prospectus Supplement - Open Market Sale Agreement Mar 2021 PEO PEO [Member] Costs related to collaboration Other Cost and Expense, Operating Sale of Stock [Axis] Sale of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities US treasury bills US Treasury Bill Securities [Member] Customer [Domain] Customer [Domain] Debt securities, available-for-sale, unrealized loss Position, number of positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Sale of future royalties Liabilities Related To Sale Of Future Royalties [Text Block] Liabilities Related To Sale Of Future Royalties Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Premium on closing stock price (as a percent) Premium on Closing Stock Price Premium on Closing Stock Price Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Arbutus Inc. Arbutus Inc. [Member] Arbutus Inc. [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Change in fair value of contingent consideration Increase (Decrease) In Fair Value Of Contingent Consideration Liability Increase (Decrease) In Fair Value Of Contingent Consideration Liability All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Loss per share Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Issued and outstanding: 188,739,044 (December 31, 2023: 169,867,414) Common Stock, Value, Issued General and administrative General and Administrative Expense Bona fide collaboration Percentage Bona fide collaboration Percentage Bona fide collaboration Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Professional fee accruals Accrued Professional Fees, Current Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Registration Statement [Axis] Registration Statement [Axis] Registration Statement Segment information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Genevant Genevant Sciences Corporation [Member] Genevant Sciences Corporation [Member] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Contingent consideration Fair value of contingent consideration Liability at beginning of the period Liability at end of the period Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Net loss attributable to common shareholders per share Earnings Per Share, Policy [Policy Text Block] Trade accounts payable Accounts Payable, Trade, Current PEO Name PEO Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Nov 2021 Registration Stmt Nov 2021 Registration Stmt [Member] Nov 2021 Registration Stmt Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Investment in Genevant Equity Method Investments and Joint Ventures Disclosure [Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Investments in marketable short-term securities Debt Securities, Available-for-Sale, Current October 2021 Prospectus Supplement October 2021 Prospectus Supplement [Member] October 2021 Prospectus Supplement Debt Securities, Unrealized Gain (Loss) Debt Securities, Unrealized Gain (Loss) Nature of business and future operations Nature of Operations [Text Block] Depreciation Depreciation, Depletion and Amortization Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Enantigen's Selling Shareholders Enantigen's Selling Shareholders [Member] Enantigen's Selling Shareholders Cash Investments and Cash Change in deferred license revenue Increase (Decrease) in Deferred Revenue Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Cumulative Collaboration Revenue Recognized Contract with Customer, Liability, Revenue Recognized Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Subsequent Events [Abstract] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Non-cash interest expense Non Cash Interest Expense Related To Sale Of Future Royalties Non Cash Interest Expense Related To Sale Of Future Royalties Entity Emerging Growth Company Entity Emerging Growth Company Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Gross proceeds from sale of royalty interest. before advisory fees Gross Proceeds From Royalty Interest Sold Gross Proceeds From Royalty Interest Sold Long Term Marketable Securities Investments in marketable securities, noncurrent [Member] Investments in marketable securities, noncurrent Jefferies LLC Jefferies LLC [Member] Jefferies LLC Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Aggregate sale price of common shares under agreement Common Stock, Value, Subscriptions Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Recovery of direct costs Recovery of Direct Costs Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Shares Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Ownership interest in equity method investment (as a percentage) Equity Method Investment, Ownership Percentage Potential milestone payments Potential Milestone Payments Represents the potential milestone payments amount. Document Fiscal Year Focus Document Fiscal Year Focus Marketable Securities [Table] Marketable Securities [Table] Summary of collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Amortization of other deferred charges Amortization of Other Deferred Charges Minimum Minimum [Member] Number of wholly-owed subsidiaries Wholly Owned Subsidiaries Included in Financial Statements Represents the number of wholly owned subsidiaries included in the reporting of the financial statements. Property and equipment, net of accumulated depreciation of $12,611 (December 31, 2023: $11,900) Property, Plant and Equipment, Net Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Development and regulatory milestones payment per licensed compound series, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per License License Agreement, Maximum Development and Regulatory Milestone Payments Per License Total Liabilities, Fair Value Disclosure Royalty guarantees commitments percentage Royalty Guarantees Commitments Percentage Represents the royalty guarantees commitments percentage. Foreign exchange (loss)/gain Gain (Loss), Foreign Currency Transaction, before Tax Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Deficit Retained Earnings [Member] Schedule of stock based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Close-out activities with vendors Business Exit Costs Basic (in USD per share) Earnings Per Share, Basic Right of use asset Operating Lease, Right-of-Use Asset Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Restructuring and related cost, number of positions eliminated, percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Expected restructuring charges Restructuring and Related Cost, Expected Cost Arrangement Duration Trading Arrangement Duration Weighted average number of common shares Weighted Average Number Of Common Shares [Abstract] Weighted average number of common shares Non-cash royalty revenue Non-cash royalty revenue Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Income taxes paid Income Taxes Paid Principles of consolidation Consolidation, Policy [Policy Text Block] Schedule of changes in fair value of contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Fair Value Investments in marketable securities, fair value Debt Securities, Available-for-Sale Arbutus Plans Arbutus Plans [Member] Arbutus Plans [Member] Gross Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Other Liabilities Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Issuance of common shares pursuant to exercise of stock options Proceeds from Stock Options Exercised Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Jan 2020 Oct 2020 and Nov 2021 Registration Stmts Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member] Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member] Non-cash interest expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Entitlement of royalties to be received Royalty Interest Sold, Maximum Royalties For Buyer Royalty Interest Sold, Maximum Royalties For Buyer Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Insider Trading Arrangements [Line Items] Share price (in USD per share) Share Price Acuitas Therapeutics, Inc. Acuitas Therapeutics Inc. [Member] Acuitas Therapeutics Inc. Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Change in fair value of contingent consideration Increase (decrease) in fair value of contingent consideration Change in fair value of liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Employee Severance Employee Severance [Member] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated depreciation of property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Entity Central Index Key Entity Central Index Key Liabilities Liabilities, Fair Value Disclosure [Abstract] Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Transaction costs on sale of royalties Transaction Costs Related To Sale Of Future Royalties Transaction Costs Related To Sale Of Future Royalties Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Fair value measurements Fair Value Disclosures [Text Block] Other Restructuring Other Restructuring [Member] Name Trading Arrangement, Individual Name Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Contingencies and Commitments [Line Items] Contingencies and Commitments [Line Items] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Money market Money Market Funds [Member] Qilu Pharmaceutical Co, LTD. Qilu Pharmaceutical Co, LTD. [Member] Qilu Pharmaceutical Co, LTD. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets Assets, Fair Value Disclosure [Abstract] Oct 2020 Registration Stmt Oct 2020 Registration Stmt [Member] Oct 2020 Registration Stmt Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of deferred collaborations and contracts revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Operating expenses Operating Expenses [Abstract] Schedule of activity related to the net liability from inception of the Agreement Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block] Liabilities Related To Sale Of Future Royalties Roll Forward US corporate bonds US Corporate Bonds [Member] US Corporate Bonds Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Unrealized gain on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Royalty interest, % interest Royalty interest, Percent interest Royalty interest, % interest Recurring Fair Value, Recurring [Member] Non-NEOs Non-NEOs [Member] Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Total operating expenses Operating Expenses Increase/(decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Registration Statement [Domain] Registration Statement [Domain] Registration Statement [Domain] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Loss from operations Operating Income (Loss) March 2022 Prospectus Supplement March 2022 Prospectus Supplement [Member] March 2022 Prospectus Supplement Aug 2020 Prospectus Supplement Aug 2020 Prospectus Supplement [Member] Aug 2020 Prospectus Supplement Revenue Revenues [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Yankee bonds Yankee Bonds [Member] Yankee Bonds Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Type of Restructuring [Domain] Type of Restructuring [Domain] Arbutus Biopharma Corp Arbutus Biopharma Corp [Member] Arbutus Biopharma Corp Laboratory equipment impairment Other Restructuring Costs